Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,459.98 -9.32 (-0.17%) Dow
38,980.84 -131.32 (-0.34%) Nasdaq
17,747.79 +30.13 (+0.17%) Bitcoin USD
61,582.51 -281.10 (-0.45%) CMC Crypto 200
1,279.68 -4.10 (-0.32%)
ITCI Aug 2024 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:29PM EDT. Market open.
| Previous close | 0.9500 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 1.4500 |
| Strike | 90.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.